Novo Nordisk As Stock Today

NVO Stock  USD 124.52  3.59  2.97%   

Performance

13 of 100

 
Low
 
High
Good

Odds Of Distress

Less than 5

 
100  
 
Zero
Very Low
Novo Nordisk is selling at 124.52 as of the 23rd of February 2024; that is 2.97% increase since the beginning of the trading day. The stock's open price was 120.93. Novo Nordisk has under 5 % chance of experiencing financial distress over the next 2 years and had a good performance during the last 90 days. Equity ratings for Novo Nordisk AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of January 2024 and ending today, the 23rd of February 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
4th of January 1982
Category
Healthcare
Classification
Health Care
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States.. The company has 4.46 B outstanding shares of which 5.46 M shares are now shorted by investors with about 1.64 days to cover. More on Novo Nordisk AS

Moving against Novo Stock

  0.8VALN Valneva SE ADR Report 28th of March 2024 PairCorr
  0.76HCM HUTCHMED DRC Earnings Call This WeekPairCorr
  0.7DYAI Dyadic International Report 3rd of April 2024 PairCorr
  0.5SLS Sellas Life Sciences Report 21st of March 2024 PairCorr
  0.47MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.42PFE Pfizer Inc Aggressive PushPairCorr

Novo Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novo Nordisk's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novo Nordisk or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO PresidentLars Jorgensen
Thematic Ideas
(View all Themes)
SEC FilingsNovo Nordisk Security & Exchange Commission EDGAR Reports
Old NameNovo Resources Corp
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Giant Impact, Baby Boomer Prospects, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Novo Nordisk report their recommendations after researching Novo Nordisk's financial statements, talking to executives and customers, or listening in on Novo Nordisk's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Novo Nordisk AS. The Novo consensus assessment is calculated by taking the average forecast from all of the analysts covering Novo Nordisk.
Financial Strength
Based on the analysis of Novo Nordisk's profitability, liquidity, and operating efficiency, Novo Nordisk AS may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. Financial strength of Novo Nordisk AS is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Shares4.4 B4.6 B
Fairly Down
Slightly volatile
Return on Assets0.30.292
Fairly Up
Slightly volatile
Net Cash Flow from Operations88.9 B108.9 B
Significantly Down
Slightly volatile
Current Liabilities183 B169.7 B
Significantly Up
Slightly volatile
Total Liabilities224.3 B207.9 B
Significantly Up
Slightly volatile
Gross Margin0.80.846
Notably Down
Slightly volatile
Total Debt29.1 B27 B
Significantly Up
Slightly volatile
Asset Turnover0.850.811
Sufficiently Up
Slightly volatile
Current Assets116.5 B139.6 B
Fairly Down
Slightly volatile
Total Assets252.4 B314.5 B
Significantly Down
Slightly volatile
Novo Nordisk's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Novo Nordisk's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Novo Nordisk's financial leverage. It provides some insight into what part of Novo Nordisk's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Novo Nordisk's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Novo Nordisk deploys its capital and how much of that capital is borrowed.
Liquidity
Novo Nordisk cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 27.01 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

88.91 Billion
Novo Nordisk AS (NVO) is traded on New York Stock Exchange in USA. It is located in Novo Alle 1, Bagsvaerd, Denmark, 2880 and employs 63,370 people. Novo Nordisk is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 559.6 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novo Nordisk's market, we take the total number of its shares issued and multiply it by Novo Nordisk's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novo Nordisk AS runs under Pharmaceuticals sector within Health Care industry. The entity has 4.46 B outstanding shares of which 5.46 M shares are now shorted by investors with about 1.64 days to cover. Novo Nordisk AS has about 37.47 B in cash with 108.91 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.57.
Check Novo Nordisk Probability Of Bankruptcy
Ownership Allocation
Novo Nordisk AS maintains a total of four billion four hundred sixty-three million fifty-nine thousand nine hundred sixty-eight outstanding shares. Roughly 91.0 % of Novo Nordisk outstanding shares are held by general public with 9.28 % by institutional investors. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novo Ownership Details

Novo Stock Price Odds Analysis

Contingent on a normal probability distribution, the odds of Novo Nordisk jumping above the current price in 90 days from now is about 1.46%. The Novo Nordisk AS probability density function shows the probability of Novo Nordisk stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Novo Nordisk has a beta of 0.2219. This indicates as returns on the market go up, Novo Nordisk average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Novo Nordisk AS will be expected to be much smaller as well. Additionally, the company has an alpha of 0.3065, implying that it can generate a 0.31 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 124.52HorizonTargetOdds Above 124.52
98.53%90 days
 124.52 
1.46%
Based on a normal probability distribution, the odds of Novo Nordisk to move above the current price in 90 days from now is about 1.46 (This Novo Nordisk AS probability density function shows the probability of Novo Stock to fall within a particular range of prices over 90 days) .

Novo Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Novo Nordisk that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novo Nordisk's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novo Nordisk's value.
InstituionRecorded OnShares
T. Rowe Price Associates, Inc.2023-12-31
7.8 M
Capital Research & Mgmt Co - Division 32023-12-31
7.1 M
State Street Corporation2023-09-30
6.7 M
Everett Harris & Co2023-12-31
6.5 M
State Farm Mutual Automobile Ins Co2023-12-31
6.1 M
Goldman Sachs Group Inc2023-09-30
4.3 M
Wcm Investment Management2023-12-31
4.2 M
Sustainable Growth Advisers, Lp2023-12-31
M
Capital World Investors2023-12-31
M
Jennison Associates Llc2023-12-31
22.5 M
Fisher Asset Management, Llc2023-09-30
14.7 M
View Novo Nordisk Diagnostics

Novo Nordisk Historical Income Statement

Novo Nordisk AS Income Statement is one of the three primary financial statements used for reporting Novo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Novo Nordisk AS revenue and expense. Novo Nordisk Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of the 23rd of February 2024, Consolidated Income is likely to drop to about 69.8 B. In addition to that, Cost of Revenue is likely to drop to about 31.1 B View More Fundamentals

Novo Stock Against Markets

Picking the right benchmark for Novo Nordisk stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Novo Nordisk stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Novo Nordisk is critical whether you are bullish or bearish towards Novo Nordisk AS at a given time. Please also check how Novo Nordisk's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Novo Nordisk without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Novo Nordisk Corporate Directors

Novo Nordisk corporate directors refer to members of a Novo Nordisk board of directors. The board of directors generally takes responsibility for the Novo Nordisk's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Novo Nordisk's board members must vote for the resolution. The Novo Nordisk board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Soeren PedersenDirector, Employee RepresentativeProfile
Kasim KutayDirectorProfile
Sylvie GregoireIndependent DirectorProfile
Mette JensenDirector, Employee RepresentativeProfile

How to buy Novo Stock?

Before investing in Novo Nordisk, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Novo Nordisk. To buy Novo Nordisk stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Novo Nordisk. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Novo Nordisk stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Novo Nordisk AS stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Novo Nordisk AS stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Novo Nordisk AS, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Novo Stock please use our How to Invest in Novo Nordisk guide.

Already Invested in Novo Nordisk AS?

The danger of trading Novo Nordisk AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Novo Nordisk is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Novo Nordisk. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Novo Nordisk AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Novo Stock analysis

When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.631
Dividend Share
9.4
Earnings Share
2.7
Revenue Per Share
51.812
Quarterly Revenue Growth
0.37
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.